Cannon Gillian
CIK: 0001833910
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 4, 2026
CORT Featured in Low-Beta Healthcare Stock List. Corcept Therapeutics was included in a recent list of low-beta healthcare stocks, highlighting its potential stability amid market concerns about interest rates. The company currently trades within its 52-week range, with a high trailing P/E ratio of 227.7. Analysts maintain an average price target of $141.00, reflecting a wide range of expectations for the stock's future performance.
Transaction History
| XENE | ▼ Sell | Open Market | 1,190 | $63K | 6/5/2026 | View on chart |
| XENE | ▲ Buy | Option Exercise | 2,645 | — | 6/1/2026 | View on chart |
| CORT | ▼ Sell | Gift | 7,393 | $0 | 9/10/2025 | View on chart |
| CORT | ▼ Sell | Tax Withholding | 3,607 | $253K | 9/4/2025 | View on chart |
| CORT | ▲ Buy | Option Exercise | 11,000 | $253K | 9/4/2025 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 8, 2026
Xenon (XENE) sees insider buying and new analyst price target
Recent filings show insiders purchased more than $1.6 million of XENE shares, marking a notable increase in insider activity. Guggenheim has started coverage of Xenon Pharmaceuticals with a price target of $73, while RBC noted that safety concerns are unlikely to delay the AZK approval pathway. The company also disclosed inducement grants to comply with Nasdaq Listing Rule 5635(c)(4).
Xenon (XENE) sees insider buying and new analyst price target. Recent filings show insiders purchased more than $1.6 million of XENE shares, marking a notable increase in insider activity. Guggenheim has started coverage of Xenon Pharmaceuticals with a price target of $73, while RBC noted that safety concerns are unlikely to delay the AZK approval pathway. The company also disclosed inducement grants to comply with Nasdaq Listing Rule 5635(c)(4).